公开(公告)号：WO2003049211A2

公开(公告)日：2003-06-12

申请号：PCT/FI2002/000963

申请日：2002-11-29

Applicant: HELSINKI UNIVERSITY OF TECHNOLOGY ,  UNIVERSITY OF OULU ,  SUNTIO, Teuvo ,  TENNO, Robert ,  TENNO, Ander

Inventor： SUNTIO, Teuvo ,  TENNO, Robert ,  TENNO, Ander

IPC: H01M

CPC classification number: H01M10/44 ,  H01M10/12 ,  H01M10/48 ,  H01M10/482

Abstract: A method and apparatus are disclosed for simulating the operation of a rechargeable battery. There is obtained (503, 553) a value for at least one parameter that describes an internal state of the battery. Said obtained value is used for calculating (504, 505, 554, 555) a prediction value for a characteristic of the battery that is observable outside the battery. These steps are repeated a multitude of times in order to simulate the operation of the battery over a certain period of time. A difference is detected (507, 556) between a calculated prediction value and a known value of a corresponding characteristic in a corresponding situation. The obtained value of said at least one parameter is corrected (507, 558) before a further prediction value calculating step by an amount that is proportional to said detected difference.

Abstract translation: 公开了一种用于模拟可充电电池的操作的方法和装置。 获得（503,553）用于描述电池的内部状态的至少一个参数的值。 所述获得的值用于计算（504,505,554,555）用于在电池外部可观察到的电池的特性的预测值。 为了在一段时间内模拟电池的操作，这些步骤重复多次。 在对应的情况下，在计算出的预测值与相应特征的已知值之间检测到差异（507,556）。 所获得的所述至少一个参数的值在进一步的预测值计算步骤之前被校正（507,558），该量与所述检测到的差成比例。

公开(公告)号：US12010763B2

公开(公告)日：2024-06-11

申请号：US17096037

申请日：2020-11-12

Applicant: University of Oulu

Inventor： Berhane Gebremedhin ,  Tuomas Paso ,  Jussi Haapola

IPC: H04W88/04 ,  H04L5/00 ,  H04W16/18 ,  H04W84/12 ,  H04W84/18

CPC classification number: H04W88/04 ,  H04L5/0055 ,  H04W16/18 ,  H04W84/12 ,  H04W84/18

Abstract: The present invention discloses a mechanism to initiate, establish, and maintain relay connectivity in a SmartBAN network while maintaining uninterrupted operations within the network. The present invention comprises the aspects of identifying and notifying an isolated node, initiating and establishing relay connectivity, maintaining the relay connectivity, and ending the relay connectivity when this is desired by either a hub, the isolated node or the nominated relay node. Some new frame formats comprising several new Information Units are also defined.

公开(公告)号：US20230322721A1

公开(公告)日：2023-10-12

申请号：US18014840

申请日：2021-07-06

Applicant: OSLO UNIVERSITETSSYKEHUS HF ,  UNIVERSITY OF OULU

Inventor： Stefan KRAUSS ,  Jo WAALER ,  Anita WEGERT ,  Ruben Gerardus George LEENDERS ,  Lari LEHTIO

IPC: C07D401/14 ,  C07D401/04 ,  C07D471/04

CPC classification number: C07D401/14 ,  C07D471/04 ,  C07D401/04

Abstract: The present invention relates to compounds of general formula (I), tautomers, stereoisomers, N-oxides, pharmaceutically acceptable salts and pro-drug thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy: wherein: a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1_3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —OH, —N(R1)2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), —SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), —SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), C and —C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —OH, —N(R1)2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), —SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), —SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and —C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); with the proviso: that when the compound is other than an N-oxide of formula (I), Z must be substituted by at least one substituent selected from —OH, —N(R3)2, —SO2N(R3)2 and —C(O)N(R4)2, preferably by at least one substituent selected from —OH, —SO2N(R3)2 and —C(O)N(R4)2. These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

公开(公告)号：US20210269419A1

公开(公告)日：2021-09-02

申请号：US17253668

申请日：2019-06-19

Applicant: OSLO UNIVERSITETSSYKEHUS HF ,  FORSCHUNGSVERBUND BERLIN E.V. ,  UNIVERSITY OF OULU

Inventor： Stefan KRAUSS ,  Marc NAZARE ,  Lari LEHTIO ,  Jo WAALER ,  Anita WEGERT ,  Ruben Gerardus George LEENDERS

IPC: C07D401/14 ,  C07D471/04 ,  C07D403/14 ,  C07D403/04 ,  C07D417/14 ,  C07D417/04 ,  C07D409/14 ,  C07D405/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04

Abstract: The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl). These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

公开(公告)号：US10694526B2

公开(公告)日：2020-06-23

申请号：US15720951

申请日：2017-09-29

Applicant: Drexel University ,  University of Oulu

Inventor： Danh H. Nguyen ,  Anton Paatelma ,  Harri Saarnisaari ,  Nagarajan Kandasamy ,  Kapil R. Dandekar

IPC: H04W72/02 ,  H04W72/08 ,  H04W74/04 ,  H04W72/04 ,  H04W16/06 ,  G06N20/00 ,  H04L12/26 ,  G06N7/00 ,  H04W16/26 ,  H04W56/00 ,  H04L12/24 ,  G06N3/12

Abstract: A learning protocol for distributed antenna state selection in directional cognitive small-cell networks is described. Antenna state selection is formulated as a nonstationary multi-armed bandit problem and an effective solution is provided based on the adaptive pursuit method from reinforcement learning. A cognitive small cell testbed, called WARP-TDMAC, provides a useful software-defined radio package to explore the usefulness of compact, electronically reconfigurable antennas in dense small-cell configurations. A practical implementation of the adaptive pursuit method provides a robust distributed antenna state selection protocol for cognitive small-cell networks. Test results confirm that directionality provides significant advantages over omnidirectional transmission which suffers high throughput reduction and complete link outages at above-average jamming or cross-link interference power.

公开(公告)号：US20170075999A1

公开(公告)日：2017-03-16

申请号：US14855885

申请日：2015-09-16

Applicant: University of Oulu

Inventor： Mika Rautiainen ,  Henri Huttunen ,  Otso Kassinen

IPC: G06F17/30

CPC classification number: G06F16/9535 ,  G06F16/437

Abstract: An enhanced method for indexing and retrieval of digital media entities is presented. Furthermore the method utilizes descriptive search queries and augmented digital media models for searching the digital media entities.

Abstract translation: 提出了一种增强数字媒体实体索引和检索的方法。 此外，该方法利用描述性搜索查询和增强的数字媒体模型来搜索数字媒体实体。

公开(公告)号：WO2019243822A1

公开(公告)日：2019-12-26

申请号：PCT/GB2019/051728

申请日：2019-06-19

Applicant: OSLO UNIVERSITETSSYKEHUS HF ,  FORSCHINGSVERBUND BERLIN E.V ,  UNIVERSITY OF OULU ,  GOLDING, Louise

Inventor： KRAUSS, Stefan ,  NAZARE, Marc ,  ANUMALA, Upendra Rao ,  LEHTIO, Lari ,  WAALER, Jo ,  WEGERT, Anita ,  LEENDERS, Ruben Gerardus George

IPC: C07D401/14 ,  C07D405/14 ,  A61K31/4196 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  A61P35/00

Abstract: The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C 1-6 alkyl (e.g. C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), C 1-6 alkoxy (e.g. C 1-3 alkoxy), -CN, -NO 2 , -N(R)2, and -SO 2 R (where each R is independently H or C 1-6 alkyl, e.g. H or C 1-3 alkyl); a C 3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C 1-6 alkyl (preferably C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), and C 1-6 alkoxy (e.g. C 1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C 1-6 alkyl (e.g C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), and C 1-6 alkoxy (e.g. C 1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C 1-6 alkyl (e.g C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), and C 1-6 alkoxy (e.g. C 1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C 1-6 alkyl (preferably C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), and C 1-6 alkoxy (e.g. C 1-3 alkoxy); or a C 3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C 1-6 alkyl (preferably C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), and C 1-6 alkoxy (e.g. C 1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C 1-6 alkyl (e.g. C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), C 1-6 alkoxy (e.g. C 1-3 alkoxy), -CN, -NO 2 , -N(R) 2 , and -SO 2 R (where each R is independently H or C 1-6 alkyl, e.g. H or C 1-3 alkyl); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C 1-6 alkyl (e.g. C 1-3 alkyl), C 1-6 haloalkyl (e.g. C 1-3 haloalkyl), C 1-6 alkoxy (e.g. C 1-3 alkoxy), -CN, -NO 2 , -N(R) 2 , and -SO 2 R (where each R is independently H or C 1-6 alkyl, e.g. H or C 1-3 alkyl). These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

公开(公告)号：WO2016146893A1

公开(公告)日：2016-09-22

申请号：PCT/FI2016/050163

申请日：2016-03-17

Applicant: UNIVERSITY OF OULU

Inventor： SALO, Tuula ,  SUTINEN, Meeri ,  SUNDQUIST, Elias ,  SUOMI, Fumi

IPC: C12N5/00 ,  C12N5/09

CPC classification number: C12N5/0693 ,  C12N5/0068 ,  C12N2533/76 ,  C12N2533/90

Abstract: The present invention provides extracellular matrix homogenate for culturing human cells in vitro comprising homogenized human leiomyoma tissue. The present invention also provides a method for producing extracellular matrix homogenate from discarded leiomyoma tissue removed from patients in routine operations.

Abstract translation: 本发明提供用于在体外培养人细胞的细胞外基质匀浆物，其包含均质化的人平滑肌瘤组织。 本发明还提供了在日常操作中从患者中除去的平滑肌瘤组织中产生细胞外基质匀浆的方法。

公开(公告)号：WO2019219930A1

公开(公告)日：2019-11-21

申请号：PCT/EP2019/062840

申请日：2019-05-17

Applicant: UNIVERSITY OF OULU

Inventor： SETHI, Jatin ,  OKSMAN, Kristiina ,  ILLIKAINEN, Mirja

IPC: C08B3/08 ,  D21C9/18

Abstract: The present invention relates to a method for preparation of a modified cellulose material, wherein the method comprises sonication of a mixture comprising a suspension of cellulose and an organic acid. It also relates to the cellulose material obtained by the method, a paper sheet, a cellulose nanopaper, as well as the use of the method for reducing the drainage time in processing of cellulose into finished products.

公开(公告)号：WO2018118868A1

公开(公告)日：2018-06-28

申请号：PCT/US2017/067228

申请日：2017-12-19

Applicant: OSLO UNIVERSITY HOSPITAL HF ,  FORSCHUNGSVERBUND BERLIN E.V. ,  UNIVERSITY OF OULU

Inventor： KRAUSS, Stefan ,  NAZARE, Marc ,  ANUMALA, Upendra Rao ,  LEHTIO, Lari ,  WAALER, Jo ,  HOLSWORTH, Dan ,  WEGERT, Anita ,  LEENDERS, Ruben Gerardus George

IPC: C07D235/26 ,  C07D403/14 ,  C07D417/14 ,  A61P35/00 ,  A61K31/4196

CPC classification number: C07D403/14 ,  A61P35/00 ,  C07D235/26 ,  C07D417/14

Abstract: The present invention relates to compounds of formula (I'), tautomers, stereoisomers, and pharmaceutically acceptable salts thereof, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy (I') (wherein: Z represents an optionally substituted, 5- or 6-membered unsaturated heterocyclic group comprising at least one nitrogen atom; L represents a 4-, 5- or 6-membered cycloalkyl group, preferably a cyclobutyl group; each R1 independently represents F, CI, Br, I, C 1-3 alkyl, C1-3 haloalkyl (e.g. -CF 3 ), -CN, -OH or -NO2, preferably F, CI, Br or 1, e.g. CI or F; each R 2 independently represents F, CI, Br, I, C 1-3 alkyl, -CN, -OH or -NO 2 , preferably F, CI, Br, I or -CN, e.g. F or -CN; X represents -NR 3 - or -0-; R 3 represents H or a C 1-3 alkyl group (e.g. methyl); n is an integer from 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2, e.g 1; and m is an integer from 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2, e.g. 0 or 1). These compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the WNT pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.